Panagiotis Antoniou
Paris, 75015, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Single-cell and in vivo profiling reveal heterogeneous and organ-specific CRISPR-Cas9 off-target and translocation outcomes.
Journal: Nature communications
Published: April 03, 2026
Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies.
Journal: Science translational medicine
Published: November 26, 2025
Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the HBG1/2 promoters.
Journal: Molecular therapy. Nucleic acids
Published: October 08, 2025
Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease.
Journal: Cell reports. Medicine
Published: May 15, 2025
Dissecting the epigenetic regulation of the fetal hemoglobin genes to unravel a novel therapeutic approach for β-hemoglobinopathies.
Journal: Nucleic acids research
Published: January 10, 2025
Unveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR.
Journal: Nature communications
Published: December 17, 2024
Dual inhibition of DNA-PK and Polϴ boosts precision of diverse prime editing systems.
Journal: Nature communications
Published: August 21, 2024
Modified pegRNAs mitigate scaffold-derived prime editing by-products.
Journal: Nature communications
Published: August 07, 2024
Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 26, 2024
Last Updated: 09/26/2026